LEVADEX

Related by string. Levadex * * MAP Pharmaceuticals LEVADEX . LEVADEX ™ . LEVADEX TM . LEVADEX orally inhaled . Patients administer LEVADEX . developing LEVADEX orally . developing LEVADEX inhaled *

Related by context. All words. (Click for frequent words.) 66 tezampanel 66 analgesic efficacy 65 MAP# 65 alvimopan 65 Phase 1b 65 bicifadine 64 CRx 64 tapentadol ER 64 Traficet EN 64 KRN# 64 rNAPc2 64 AEGR 63 Empatic 63 oral rivaroxaban 63 MoxDuo 63 Anturol 63 TOLAMBA 63 Phase 2a clinical 63 CIMZIA TM 63 NGX# 63 placebo controlled clinical 63 Bezielle 63 lesinurad 63 deforolimus 63 XGEVA 62 pomalidomide 62 Phase 2a trial 62 elagolix 62 visilizumab 62 pseudobulbar affect PBA 62 INCB# [001] 62 teriflunomide 62 cannabinor 62 PXD# 62 HZT 62 Phase 2b study 62 linaclotide 62 avanafil 62 AeroLEF TM 62 ACTEMRA TM 62 phase IIa clinical 62 APF# 62 IRX 2 62 PRT# 62 Triolex 62 JAK inhibitor 62 MoxDuo TM IR 62 PS# [001] 61 desvenlafaxine succinate 61 ZOLINZA 61 telcagepant 61 forodesine 61 diabetic neuropathic pain 61 eltrombopag 61 Phase IIa clinical 61 Dyloject TM 61 Azedra 61 HspE7 61 CoFactor 61 tolerability profile 61 icatibant 61 active comparator 61 PEG Interferon lambda 61 Zenvia 61 LEVADEX ™ 61 HuMax EGFr 61 oral ridaforolimus 61 LymphoStat B 61 ADX# 61 Phase IIa 61 eniluracil 61 clinically meaningful 61 Neurodex 61 CCX# 61 elotuzumab 61 TREANDA 61 opioid induced bowel dysfunction 61 EFAPROXYN 61 Phase 2a 61 Azixa 61 Adlea 61 CR# vcMMAE 61 dose escalation 61 Inhalation Solution 61 axitinib 61 oral prodrug 61 rFIXFc 61 CIMZIA ™ 61 tocilizumab 61 ALKS 61 ALGRX 60 Phase Ib 60 tolerability 60 pharmacokinetic profile 60 MNTX 60 aflibercept 60 DDP# 60 Gabapentin GR 60 Synavive 60 Dextofisopam 60 hylan GF 60 NVA# 60 pharmacodynamic profile 60 Oral NKTR 60 cangrelor 60 MGCD# [001] 60 Zerenex 60 investigational drug 60 lacosamide 60 tanespimycin 60 CIMZIA TM certolizumab pegol 60 Phase Ib study 60 febuxostat 60 certolizumab pegol 60 Ventavis 60 custirsen 60 pertuzumab 60 APTIVUS r 60 Allovectin 7 R 60 PRX # 60 NP2 Enkephalin 60 prucalopride 60 Instanyl 60 dacetuzumab 60 dosage regimens 60 OncoVEX GM CSF 60 HGS ETR1 60 torezolid phosphate 60 Phase 1b trial 60 ACTEMRA 60 PRECiSE 60 Anturol TM 60 Cloretazine R VNP#M 60 INCB# [002] 60 tolvaptan 60 dose escalation trial 60 Targretin 60 Pimavanserin 60 brentuximab vedotin 60 RSD# 60 Chrysalin 60 Phase IIa trial 59 INT# [002] 59 BEMA Buprenorphine 59 vidofludimus 59 Sym# 59 treprostinil 59 BROVANA 59 atacicept 59 phase IIb clinical 59 microplasmin 59 PEG PAL 59 trodusquemine 59 GAMMAGARD 59 evaluating tivozanib 59 velafermin 59 edoxaban 59 Ereska 59 eculizumab 59 Phase 2b trial 59 nab paclitaxel 59 BRIM2 59 Tezampanel 59 DU #b 59 apremilast 59 decitabine 59 confirmatory Phase III 59 pivotal Phase III 59 PRISTIQ 59 Zelrix 59 ARRY 59 Menerba 59 REMINYL ® 59 Vilazodone 59 GLYX 59 vorinostat 59 Fibrillex TM 59 Icatibant 59 OMNARIS HFA 59 6R BH4 59 otelixizumab 59 SCH # 59 JANUVIA 59 bosutinib 59 ganetespib 59 pharmacokinetics PK 59 sorafenib tablets 59 Phase 1b dose escalation 59 Clonicel 59 NEBIDO 59 enzastaurin 59 tasocitinib 59 Entereg R 59 Ketotransdel 59 VAPRISOL 59 Phase 2b clinical 59 CANCIDAS 59 BAY #-# 59 ONCONASE 59 zonisamide SR 59 dasatinib 59 neratinib 59 monotherapy 59 BEMA TM Fentanyl 59 Corlux 59 LIALDA 59 MoxDuo IR 59 efficacy tolerability 59 oral FTY# 59 dosing cohorts 59 pharmacodynamic effects 59 incyclinide 59 Imprime PGG 59 aplindore 59 pramlintide 59 TORISEL 59 Aclidinium 59 satraplatin 59 secondary efficacy endpoints 59 mapatumumab 59 vandetanib 58 GATTEX 58 obatoclax 58 Aflibercept 58 ostarine 58 CIPN 58 zileuton 58 Elotuzumab 58 Firazyr 58 Virulizin ® 58 QNEXA 58 interferon gamma 1b 58 iniparib 58 picoplatin 58 PDE4 inhibitor 58 Welchol 58 fidaxomicin 58 trospium 58 antibody MAb 58 mg dose 58 CCX# B 58 alvespimycin 58 PROMACTA 58 RG# ITMN 58 YONDELIS 58 AZOR 58 phase 2a 58 CorVue ™ 58 brivaracetam 58 ONGLYZA 58 bortezomib 58 oxymorphone ER 58 ILLUMINATE 58 dabigatran etexilate 58 Alfimeprase 58 relapsed multiple myeloma 58 Trexima 58 lintuzumab 58 PREOS R 58 exenatide 58 ponatinib 58 pharmacodynamic 58 ZYBRESTAT 58 ISENTRESS 58 RAPAFLO 58 FOLOTYN 58 reslizumab 58 Dacogen injection 58 Amrubicin 58 ARCOXIA 58 abatacept 58 Keppra R 58 riociguat 58 Tyrima 58 rotigotine 58 PRTX 58 CTAP# Capsules 58 CINQUIL 58 PRE SURGE 58 MGd 58 Octreolin 58 viral kinetic 58 Ketotransdel ® 58 ACZ# 58 xanthine oxidase inhibitor 58 Phase IIb 58 Ketotransdel TM 58 Phase Ib clinical 58 adecatumumab 58 thymalfasin 58 NUEDEXTA 58 subcutaneous formulation 58 MEND CABG 58 metastatic hormone refractory 58 ruxolitinib 58 Dapagliflozin 58 AeroLEF 58 tecarfarin 58 Phenoptin 58 ARCALYST 58 dosing regimens 58 RSD# oral 58 hour bronchodilation 58 bronchodilation 58 Cimzia TM 58 tasimelteon 58 CK # 58 lubiprostone 58 Phase III clinical 58 mGluR5 negative 58 OPAXIO 58 IIa trial 58 Acute Ischemic Stroke 58 PEG INTRON 58 velafermin belinostat 58 ISIS # 58 teduglutide 58 CCR9 antagonist 58 HuMax CD# 58 glufosfamide 58 RLY# 58 LEVADEX TM 58 Phase 2b 58 GSK# [001] 58 selective androgen receptor modulator 58 Perifosine 58 histone deacetylase HDAC inhibitor 58 cariprazine 58 TYKERB 58 Bronchitol 58 FOLFOX4 58 aliskiren 57 acyclovir Lauriad R 57 phase IIa 57 Phase IIb trials 57 celgosivir 57 valopicitabine 57 IMA# 57 posaconazole 57 CYCLOSET 57 GALNS 57 telbivudine 57 achieved statistical significance 57 Locteron 57 Perforomist ™ Inhalation Solution 57 Symadex 57 ARIKACE 57 AGGRASTAT ® 57 Androxal TM 57 mGluR2 positive 57 relapsing multiple sclerosis 57 pralatrexate 57 fosbretabulin 57 AGILECT R 57 DAPT 57 bendamustine 57 palifosfamide 57 methylnaltrexone 57 PEGylated interferon beta 1a 57 evaluating REVLIMID 57 AGILECT ® 57 Cleviprex TM clevidipine 57 cancer neuroendocrine tumor 57 dose escalation clinical 57 ARIKACE ™ 57 HGS ETR2 57 Panzem R NCD 57 R#/MEM # 57 talactoferrin 57 pazopanib 57 Golimumab 57 favorable pharmacokinetic profile 57 Bicifadine 57 SILENOR TM 57 ularitide 57 DAVANAT 57 Phase IIb trial 57 GEM OS2 57 demonstrated clinically meaningful 57 naproxcinod 57 maximally tolerated dose 57 Generx 57 PHX# 57 Perforomist TM Inhalation Solution 57 lomitapide 57 Carfilzomib 57 CRMD# 57 LY# [003] 57 TELCYTA 57 Fampridine SR 57 clevidipine 57 initiate Phase 1b 57 ICA # 57 peripherally acting 57 intermittent dosing 57 PSMA ADC 57 FOLPI 57 azacitidine 57 Rezular 57 class mGluR5 inhibitor 57 AMITIZA 57 CaPre TM 57 ofatumumab 57 Levadex 57 C1 INH 57 IMGN# 57 Stedivaze 57 dextromethorphan quinidine 57 AP# [003] 57 Ophena TM 57 Zenvia TM 57 Serdaxin 57 MAGE A3 ASCI 57 tolerability profiles 57 Randomized Phase 57 blinded randomized placebo controlled 57 TNF inhibitor 57 XmAb# 57 LY# [002] 57 bosentan 57 DuraSite 57 placebo controlled Phase 57 INVEGA ® 57 Marqibo 57 Ixempra 57 RG# [001] 57 Hyphanox 57 APTIVUS 57 CB2 selective receptor agonist 57 amrubicin 57 ProSavin 57 laquinimod 57 CORLUX 57 fenofibric acid 57 MERLIN TIMI 57 arzoxifene 57 MLN# 57 RE SURGE 57 Zenvia ™ 57 Phase Ia 57 Adalimumab 57 pharmacokinetic PK 57 Dual Opioid 57 CINTREDEKIN BESUDOTOX 57 HCV SPRINT 57 TLUS 57 PSN# [002] 57 investigational compound 57 imetelstat 57 rFVIIa 57 orally inhaled migraine 57 mycophenolate mofetil 57 Phase 1a clinical 57 ketoprofen patch 57 antiplatelet agent 57 LibiGel Phase III 57 Hsp# Inhibitor 57 EXPAREL TM 57 administered subcutaneously 57 Intermezzo R 57 Bendavia 57 NLX P# 57 Entereg 57 INCB# [003] 57 noninferiority 57 μg dose 57 ONTAK 57 Panzem R 57 RAPTIVA 57 primary endpoint 57 abiraterone acetate 57 baminercept 57 DASISION 57 investigational humanized monoclonal antibody 57 severe gastroparesis 57 Phase 1a 57 Cardio Vascu Grow 57 Archexin 57 ATACAND 57 HCV RESPOND 2 57 postoperative ileus POI 57 Aurexis 57 standard chemotherapy regimen 57 motesanib 57 Ceplene/IL-2 57 dimebon 57 placebo controlled 56 adult chronic ITP 56 ELND# 56 Altastaph 56 telaprevir dosed 56 pharmacokinetic profiles 56 Excellarate 56 mertansine 56 albiglutide 56 TELINTRA 56 Ticagrelor 56 lurasidone 56 KRAS mutations occur 56 mipomersen 56 ramelteon 56 PREZISTA r 56 pharmacodynamics 56 bevirimat 56 AZILECT R 56 Genz # 56 AMRIX 56 desvenlafaxine 56 Cladribine Tablets 56 Frova R 56 OncoGel 56 Phase IIIb clinical 56 CONSERV 56 galiximab 56 Trofex 56 Exherin TM 56 double blinded placebo 56 ENDEAVOR IV 56 sunitinib malate 56 vicriviroc 56 OXi# 56 Aloxi injection 56 oxybutynin gel 56 relapsed myeloma 56 KAPIDEX 56 Ranexa 56 Alpharadin 56 refractory gout 56 HUMIRA 56 Zenvia Phase III 56 limiting toxicity 56 Talabostat 56 injectable formulation 56 oral diclofenac 56 Cimzia ® certolizumab pegol 56 Defibrotide 56 anti EGFR antibody 56 ataluren 56 Phase 1b clinical 56 aclidinium 56 NXL# 56 SEROQUEL 56 bazedoxifene conjugated estrogens 56 opioid analgesia 56 phase IIb study 56 ocrelizumab 56 CUDC 56 catheter occlusion 56 Treximet 56 blinatumomab 56 NEVO ™ 56 pitavastatin 56 BENICAR HCT 56 APOPTONE 56 telaprevir VX 56 FROVA 56 Q#IR 56 LEXIVA r 56 EXPAREL ™ 56 MultiStem 56 NasalFent 56 paliperidone palmitate 56 pharmacokinetic 56 Pegasys ® 56 GRN#L 56 aflibercept VEGF Trap 56 randomized Phase III 56 Dyloject 56 CIMZIA 56 NATRECOR R 56 perifosine 56 #mg dose [003] 56 BEMA TM LA 56 Ozarelix 56 Zemplar Capsules 56 EVIZON 56 RGB # 56 carfilzomib 56 Pralatrexate 56 Combo Stent 56 tgAAC# 56 SinuNase 56 ADAGIO study 56 Omacetaxine 56 Lacosamide 56 Amigal 56 Phase IIB 56 Capesaris 56 Tarceva TM 56 Tavocept 56 crizotinib PF # 56 Ambrisentan 56 Phase Ib clinical trials 56 pramipexole 56 placebo controlled studies 56 ThermoDox 56 telmisartan 56 RDEA# 56 Staccato loxapine 56 phase IIIb 56 cobiprostone 56 Staccato prochlorperazine 56 ELACYT 56 DexaSite 56 Cimzia ® 56 ascending doses 56 lixisenatide 56 liposomal formulation 56 peginterferon alfa 2a 56 Phase III placebo controlled 56 Durezol 56 TRV# [001] 56 Tolvaptan 56 infliximab 56 clinically meaningful reductions 56 phase Ib 56 darapladib 56 palonosetron 56 dose cohorts 56 inhaled formulation 56 Prosaptide 56 Ostarine 56 preclinical efficacy 56 cilengitide 56 Amplimexon 56 oral formulation 56 Fludara 56 dose regimens 56 valsartan 56 EndoTAG TM -1 56 zolmitriptan 56 pharmacodynamic PD 56 post herpetic neuralgia PHN 56 Excellarate TM 56 Phase #b/#a trial 56 EOquin TM 56 COPAXONE R 56 TPI ASM8 56 entecavir 56 REMICADE ® 56 Fx #A 56 VELCADE 56 Glufosfamide 56 virus HCV protease inhibitor 56 Xcytrin 56 diabetic gastroparesis 56 vernakalant 56 sapacitabine 56 clinical pharmacology studies 56 L MTP PE 56 Lung Rx 56 CA4P 56 VA# [002] 56 HCD# [002] 56 APRISO 56 Viprinex 56 XIAFLEX 56 octreotide 56 novel histone deacetylase 56 oral deforolimus 56 chlorambucil 56 diabetic peripheral neuropathic DPN 56 subcutaneously administered 56 diarrhea predominant irritable 56 LibiGel ® 56 PD LID 56 humanized monoclonal antibody 56 adipiplon 56 antitumor activity 56 Arikace 56 PEG SN# 56 Solid Tumors 56 Xanafide 56 Cinryze TM 56 HGS# 56 biologic therapy 56 SNRI 56 Anturol ® 56 Taxotere R 56 ALVESCO 56 paliperidone ER 56 EMBEDA ™ 56 JVRS 56 Milnacipran 56 Initiated Phase 56 pivotal Phase 56 Pharmacokinetic studies 56 IPL# 56 TMC# [002] 56 multiple ascending dose 56 BCX# 56 davunetide intranasal AL 56 oxycodone CR 56 ULORIC 56 elinogrel 56 optimal dosing 56 Ocrelizumab 56 neurologic progression 56 Besivance 56 interferon beta 1b 56 L BLP# 56 cediranib 56 safety tolerability 56 label multicenter Phase 56 sipuleucel T 56 Northera 56 doripenem 56 primary efficacy endpoints 56 cathepsin K inhibitor 56 schizophrenia CIAS 55 Pruvel 55 iloprost 55 Vandetanib 55 pharmacokinetic PK study 55 Telintra 55 T Pred 55 SYMBICORT 55 romidepsin 55 aripiprazole 55 TYZEKA 55 PRX# 55 ongoing Phase 1b 55 HuLuc# 55 tiotropium 55 plus dexamethasone 55 morphometric vertebral fractures 55 AZILECT 55 varespladib 55 OHR/AVR# 55 VEGF Trap 55 docetaxel Taxotere R 55 tamibarotene 55 Vernakalant 55 MYCAMINE 55 veltuzumab 55 Vectibix 55 NUVIGIL 55 alicaforsen enema 55 systemically administered 55 Pirfenidone 55 Omacetaxine mepesuccinate 55 eprotirome 55 pharmacodynamic properties 55 AIR CF1 55 PROCHIEVE 8 55 APPRAISE 55 dyskinesia PD LID 55 octreotide implant 55 DIFICID 55 CXA 55 Contrave# 55 daclizumab 55 regorafenib 55 pradefovir 55 TriRima 55 opioid induced constipation 55 Phase 2a clinical trials 55 PEGASYS ® 55 SNT MC# 55 primary efficacy endpoint 55 Troxatyl 55 STRIDE PD 55 teriparatide 55 ORENCIA ® 55 FOLFIRI 55 Pivotal Phase 55 PMX # 55 multicenter Phase 55 angiogenesis inhibitor 55 Diabetic Macular Edema 55 rosuvastatin #mg 55 Tiotropium 55 label dose escalation 55 Meets Primary Endpoint 55 MEND CABG II 55 SAPHRIS 55 long acting muscarinic 55 randomized Phase IIb 55 Laquinimod 55 octreotide LAR 55 Romiplostim 55 romiplostim 55 Asentar 55 Betaferon ® 55 Lupuzor ™ 55 FASLODEX 55 temsirolimus 55 ruboxistaurin 55 TAXUS ATLAS 55 efficacy endpoints 55 Viramidine 55 oral anticoagulant 55 Phase III Pivotal 55 SPRYCEL ® 55 dirucotide 55 Interferon alpha 55 Aliskiren 55 tipranavir 55 RhuDex ® 55 mg doses 55 bazedoxifene 55 anakinra 55 #D#C# 55 urocortin 2 55 Locteron ® 55 FTY# 55 Quinamed 55 ExTRACT TIMI 55 LATUDA 55 pharmacokinetic equivalence 55 safety tolerability pharmacokinetics 55 Keppra ® 55 Phase Ib II 55 CYPHER R Sirolimus eluting 55 Teriflunomide 55 DermaVir Patch 55 tolerated dose MTD 55 COU AA 55 LEVAQUIN 55 clinical trials Multikine 55 Avanafil 55 Pivotal Phase III 55 Vaprisol 55 NOXAFIL 55 HER2 positive metastatic breast 55 Tamibarotene 55 Gemzar ® 55 lumiliximab 55 mg QD 55 etanercept 55 PRADAXA 55 Augment Injectable 55 tesmilifene 55 Telaprevir 55 Acetavance 55 Natalizumab 55 Sapacitabine 55 plus prednisone 55 pexelizumab 55 PROCHYMAL 55 CD# antibody [001] 55 CYT# 55 CD3 monoclonal antibody 55 Microplasmin 55 ambrisentan 55 Phase III 55 TACI Ig 55 mitoxantrone 55 Nexavar ® 55 canakinumab 55 Nasulin 55 investigational compounds 55 EDEMA3 55 DOXIL 55 dopamine partial agonist 55 lexidronam injection 55 compound INCB# 55 TREDAPTIVE 55 pioglitazone 55 FOLFOX6 chemotherapy regimen 55 STELARA 55 ENBREL 55 investigational antiplatelet agent 55 comparator arm 55 CCR5 mAb 55 iSONEP 55 dosing schedules 55 AVONEX ® 55 PA# [002] 55 docetaxel Taxotere ® 55 briakinumab 55 Tesetaxel 55 ulimorelin 55 acute PAO 55 Urocortin 2 55 phase IIb 55 GEM OS1 55 omacetaxine 55 FFNS 55 THALOMID 55 afatinib 55 pegylated interferons 55 ONTARGET 55 Randomized Double blind 55 pan HDAC inhibitor 55 LUNESTA 55 pegloticase 55 denosumab 55 Treanda 55 Riquent 55 dose cohort 55 VFEND 55 LE DT 55 tafamidis 55 Zingo TM 55 iloperidone 55 Xyrem ® 55 LEP ETU 55 pharmacodynamics PD 55 salmeterol fluticasone 55 selective modulator 55 Exelixis XL# 55 FIRAZYR 55 Saforis 55 Phase #/#a 55 Ophena 55 voreloxin 55 Contrave 55 Focalin XR 55 Androxal 55 TOCOSOL Paclitaxel 55 fluticasone salmeterol 55 vilazodone 55 HRPC 55 CAELYX 55 IV bolus 55 antiarrhythmic drug 55 ToGA 55 Ceflatonin R 55 SEROQUEL XR 55 Cethromycin 55 intravenous formulation 55 mg BID 55 Vicinium TM 55 PDX pralatrexate 55 #mg doses [002] 55 ascending dose 55 Reverset 55 ALVESCO HFA 55 Protelos 55 pain palliation 55 glatiramer acetate 55 INC# 55 orBec 55 herpetic keratitis 55 Debio 55 dose escalation Phase 55 prospective randomized controlled 55 carboplatin paclitaxel 55 Panitumumab 55 Zolpimist 55 AEG# 55 evaluable patients 55 adalimumab 55 castrate resistant prostate cancer 55 ABSORB trial 55 dexanabinol 55 Albuferon 55 Actemra 55 intranasal formulation 55 SinuNase TM 55 ITMN 55 Civacir 55 Bortezomib 55 EOquin 55 octreotide acetate 55 sumatriptan naproxen sodium 55 opioid bowel dysfunction 55 Linaclotide 55 omega interferon 55 orally bioavailable 55 Iluvien 55 AQ4N 55 AzaSite Plus 55 EVEREST II 55 pharmacokinetic PK profile 55 ZACTIMA 55 ORENCIA R 55 alemtuzumab Campath 55 CORT # 55 placebo controlled trials 55 VELCADE melphalan 55 GFT# 55 gefitinib 55 denufosol 55 phase IIb trial 55 Hsp# inhibitor 55 secondary endpoints 55 rHuPH# 55 SPRYCEL 55 iclaprim 55 sorafenib Nexavar 55 RoACTEMRA 55 safinamide 55 Cethrin 54 MYDICAR 54 NEXIUM 54 Serada 54 azilsartan medoxomil 54 aclidinium bromide 54 Pharmacokinetic PK 54 nalbuphine ER 54 Darusentan 54 MYDICAR ® 54 Cotara 54 tapentadol IR 54 antihypertensive agents 54 candidate Zenvia 54 efficacy endpoint

Back to home page